Abstract

NANOEMULSION: DIRECT NOSE-TO-BRAIN DELIVERY

Zeeshan Ahmad*, Zeba Parveen, Abdul Samad Basheer and Md. Zishan

ABSTRACT

The blood brain barrier (BBB) one of the strictest barriers of in- vivo therapeutic drug delivery. The barriers are restricted exchange of hydrophilic compounds, small proteins and charged molecules between plasma and central nervous system (CNS). For decades, BBB has prevented the use of many therapeutic agents for treating Alzheimer‟s disease, stroke, brain tumor, head injury, spinal cord injury, depression, anxiety and other CNS disorders. The emerging approach is by passing the BBB by intranasal delivery, which provides a practical, noninvasive, rapid and simple method to deliver the therapeutic agents to the CNS. Intranasal delivery does not require any modification of the therapeutic agents. A wide variety of therapeutic agents, including both small molecules and macromolecules can be successfully delivered, including to the CNS, using the intranasal method. Advantage of intranasal delivery are Bypasses the BBB and targets the CNS, reducing systemic exposure and thus systemic side effects and Avoids destruction in the gastrointestinal tract, hepatic “first pass” elimination and gut wall metabolism, allowing increased, reliable bioavailability.

Keywords: Alzheimer?s disease; BBB; CNS; first pass elimination; intranasal delivery.